Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q4 FY19 results · Jan–Mar 2019
Sun Pharma Advanced Research Company reported revenue from operations of ₹84.83 crore and net loss of ₹9.35 crore for Q4 FY19 (Jan–Mar 2019), on a standalone basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 84.83 | — | — | 19.88 | +326.7% |
| Other income | 4.43 | — | — | 3.28 | +35.1% |
| Total income | 89.26 | — | — | 23.16 | +285.4% |
| Profit before tax | (9.35) | — | — | (69.02) | Loss narrowed |
| Net profit for the period | (9.35) | — | — | (69.02) | Loss narrowed |
| EPS, basic (₹) | (0.37) | — | — | (2.72) | Loss narrowed |
| Net margin (%) | -11.0 | — | -347.2 |
Standalone
- Filed with BSE
- 08 May 2019, 11:57 IST
- Board meeting
- 07 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE